These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39387235)

  • 1. Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies.
    Aguirre F; Andrade R
    J Comp Eff Res; 2024 Nov; 13(11):e240109. PubMed ID: 39387235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ravulizumab: A Review in Generalised Myasthenia Gravis.
    Kang C
    Drugs; 2023 Jun; 83(8):717-723. PubMed ID: 37166620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
    van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S
    Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.
    Vu T; Ortiz S; Katsuno M; Annane D; Mantegazza R; Beasley KN; Aguzzi R; Howard JF
    J Neurol; 2023 Jun; 270(6):3129-3137. PubMed ID: 36890354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
    Vu T; Meisel A; Mantegazza R; Annane D; Katsuno M; Aguzzi R; Enayetallah A; Beasley KN; Rampal N; Howard JF
    NEJM Evid; 2022 May; 1(5):EVIDoa2100066. PubMed ID: 38319212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.
    Howard JF; Vu T; Mantegazza R; Kushlaf H; Suzuki S; Wiendl H; Beasley KN; Liao S; Meisel A;
    Muscle Nerve; 2024 May; 69(5):556-565. PubMed ID: 38380691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
    Meisel A; Annane D; Vu T; Mantegazza R; Katsuno M; Aguzzi R; Frick G; Gault L; Howard JF;
    J Neurol; 2023 Aug; 270(8):3862-3875. PubMed ID: 37103755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence.
    Vu T; Wiendl H; Katsuno M; Reddel SW; Howard JF
    Neuropsychiatr Dis Treat; 2023; 19():2639-2655. PubMed ID: 38059203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.
    Tokuyasu D; Suzuki S; Uzawa A; Nagane Y; Masuda M; Konno S; Kubota T; Samukawa M; Sugimoto T; Ishizuchi K; Oyama M; Yasuda M; Akamine H; Onishi Y; Suzuki Y; Kawaguchi N; Minami N; Kimura T; Takahashi MP; Murai H; Utsugisawa K
    Ann Clin Transl Neurol; 2024 May; 11(5):1338-1346. PubMed ID: 38572524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study.
    Habib AA; Sacconi S; Antonini G; Cortés-Vicente E; Grosskreutz J; Mahuwala ZK; Mantegazza R; Pascuzzi RM; Utsugisawa K; Vissing J; Vu T; Wiendl H; Boehnlein M; Greve B; Woltering F; Bril V
    Ther Adv Neurol Disord; 2024; 17():17562864241273036. PubMed ID: 39297052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
    Muppidi S; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Nowak RJ; Andersen H; Casasnovas C; de Bleecker JL; Vu TH; Mantegazza R; O'Brien FL; Wang JJ; Fujita KP; Howard JF;
    Muscle Nerve; 2019 Jul; 60(1):14-24. PubMed ID: 30767274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ravulizumab for the treatment of myasthenia gravis.
    Vanoli F; Mantegazza R
    Expert Opin Biol Ther; 2023 Mar; 23(3):235-241. PubMed ID: 36852670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
    Habib AA; Benatar M; Vu T; Meisel A; Attarian S; Katsuno M; Liao S; Beasley KN; Howard JF
    Eur J Neurol; 2024 Dec; 31(12):e16490. PubMed ID: 39373062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.
    Katyal N; Govindarajan R; Goyal N; Muley S; Muppidi S
    Front Neurol; 2024; 15():1378080. PubMed ID: 38919970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
    Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF;
    Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
    Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use.
    Heo YA
    CNS Drugs; 2023 May; 37(5):467-473. PubMed ID: 37000339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ravulizumab in adults and children with atypical hemolytic uremic syndrome: a plain language summary of three studies.
    Nowicki M; Printza N
    J Comp Eff Res; 2024 Nov; 13(11):e240103. PubMed ID: 39387237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consistent improvement with eculizumab across muscle groups in myasthenia gravis.
    Mantegazza R; O'Brien FL; Yountz M; Howard JF;
    Ann Clin Transl Neurol; 2020 Aug; 7(8):1327-1339. PubMed ID: 32700461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.